AlloVir, Inc. (NASDAQ:ALVR) Short Interest Up 6.8% in April

AlloVir, Inc. (NASDAQ:ALVRGet Rating) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 7,180,000 shares, an increase of 6.8% from the April 15th total of 6,720,000 shares. Based on an average trading volume of 276,900 shares, the short-interest ratio is currently 25.9 days.

Insiders Place Their Bets

In other news, CEO Diana Brainard sold 8,408 shares of the stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $3.71, for a total transaction of $31,193.68. Following the sale, the chief executive officer now directly owns 921,164 shares of the company’s stock, valued at $3,417,518.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 9,973 shares of company stock valued at $37,000. Insiders own 39.97% of the company’s stock.

Hedge Funds Weigh In On AlloVir

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in AlloVir during the third quarter worth about $25,000. Point72 Middle East FZE bought a new position in shares of AlloVir during the 4th quarter valued at about $26,000. Nisa Investment Advisors LLC grew its position in shares of AlloVir by 33.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,210 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the period. Occudo Quantitative Strategies LP bought a new stake in AlloVir during the 2nd quarter worth approximately $48,000. Finally, Virtu Financial LLC bought a new position in AlloVir in the second quarter valued at approximately $55,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ALVR. SVB Leerink dropped their price objective on AlloVir from $25.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, January 23rd. SVB Securities increased their price objective on shares of AlloVir from $16.00 to $19.00 in a report on Wednesday, April 26th. Finally, Morgan Stanley reduced their price objective on shares of AlloVir from $27.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, January 27th.

AlloVir Trading Up 11.2 %

AlloVir stock opened at $4.28 on Tuesday. The firm has a market capitalization of $400.56 million, a P/E ratio of -2.14 and a beta of 0.72. The business has a 50-day moving average of $4.16 and a 200-day moving average of $5.61. AlloVir has a 1 year low of $3.17 and a 1 year high of $10.29.

AlloVir (NASDAQ:ALVRGet Rating) last issued its quarterly earnings data on Wednesday, February 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.14. Research analysts anticipate that AlloVir will post -1.91 EPS for the current fiscal year.

About AlloVir

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Further Reading

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with's FREE daily email newsletter.